Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "stroke"

101 News Found

StanPlus appoints Gurjit Singh as COO and Founding Member
People | May 02, 2022

StanPlus appoints Gurjit Singh as COO and Founding Member

He will be leading the business, operations, P&L, and growth strategy for StanPlus


GOQii to foray into UK patient care with GBP 10 million investment
Startup | April 25, 2022

GOQii to foray into UK patient care with GBP 10 million investment

Partnership with Modality, award-winning GP super partnership


Data indicates homeopathy effective in management of long Covid
News | April 10, 2022

Data indicates homeopathy effective in management of long Covid

Dr. Kalyan Banerjee's Clinic developed a homeopathy prophylaxis protocol for the prevention of Covid-19 as soon as the pandemic began


Alembic gets USFDA tentative approval for dabigatran etexilate capsules
Drug Approval | April 07, 2022

Alembic gets USFDA tentative approval for dabigatran etexilate capsules

The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Pradaxa Capsules of Boehringer lngelheim


BioFluidica to introduce next-generation biomarker isolation platform
Biotech | April 06, 2022

BioFluidica to introduce next-generation biomarker isolation platform

BioFluidica LiquidScan harnesses the power of microfluidics


Ondexxya approved in Japan for reversal of acute major bleeds in patients on Factor Xa inhibitors
Drug Approval | March 30, 2022

Ondexxya approved in Japan for reversal of acute major bleeds in patients on Factor Xa inhibitors

Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding


Ozempic 2.0 mg approved in the US for the treatment of type 2 diabetes
Drug Approval | March 29, 2022

Ozempic 2.0 mg approved in the US for the treatment of type 2 diabetes

Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults


Tarlige tablets approved in Japan for treatment of patients with neuropathic pain
Drug Approval | March 28, 2022

Tarlige tablets approved in Japan for treatment of patients with neuropathic pain

In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP


Pfizer voluntary recall of drugs in the US
News | March 23, 2022

Pfizer voluntary recall of drugs in the US

Voluntary nationwide recall of lots of Accuretic (quinapril HCl/hydrochlorothiazide), quinapril and hydrochlorothiazide tablets, and quinapril HCl/hydrochlorothiazide tablets due to n-nitroso- quinapril content


Bristol Myers Squibb to demonstrate growing cardiovascular portfolio
Biotech | March 22, 2022

Bristol Myers Squibb to demonstrate growing cardiovascular portfolio

New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease